Oral Communications 4: Pituitary and Neuroendocrinology 1

ea0081oc4.1 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Significant weight loss resulted in reduced levothyroxine requirements during a tesomet trial of hypopituitary patients with acquired hypothalamic obesity

Klose Marianne , Huynh Kim , Tfelt Jacob , Krogsgaard Kim , Drejer Jorgen , Byberg Sarah , Madsbad Sten , Magkos Faidon , Aharaz Abdellatif , Edsberg Berit , Astrup Arne , Feldt-Rasmussen Ulla

Objective: Hypothalamic obesity results in severe weight-gain and increased risk of cardiovascular and metabolic mortality. We aimed to assess the safety and efficacy of Tesomet (tesofensine plus metoprolol), and ongoing requirements in pituitary hormone replacement adjustments in adults with acquired hypothalamic obesity, a rare disease with no approved therapyResearch design, patients and methodsTwenty-one adults with hypothalami...

3 shares

ea0081oc4.2 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Measurements of growth hormone in neonatal screening cards as a non-invasive and feasible tool: reference values in healthy term newborns

Giacchetti Federico , Vidali Matteo , Sangiorgio Andrea , Rodari Giulia , Vantaggiato Chiara , Di Modugno Adriana , Morniroli Daniela , Colombo Lorenzo , Profka Eriselda , Dall'Antonia Alberta , Mosca Fabio , Ceriotti Ferruccio , Arosio Maura , Gianni' Maria Lorella , Giavoli Claudia

Background: Severe congenital growth hormone deficiency (cGHD) is a rare but potentially life-threatening condition. Even though random growth hormone (GH) can confirm cGHD during the first week of life, the diagnosis remains extremely challenging in the absence of reliable reference values in healthy neonates and thus of a best diagnostic cut-off.Aims: First, to provide solid reference values for GH concentrations in term newborns, by means of a non-inv...

0 shares

ea0081oc4.3 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Long-term efficacy and safety data for oral octreotide capsules in acromegaly: mpowered trial open-label extension phase

Fleseriu Maria , Molitch Mark E , Dreval Alexander , Pokramovich Yulia G , Bondar Irina , Poteshkin Yury E , Macut Djuro P , Obermayer-Pietsch Barbara , Gilgun-Sherki Yossi , Haviv Asi , Biermasz Nienke , Melmed Shlomo , Strasburger Christian J

Background: Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States. The MPOWERED trial (NCT02685709) showed that OOC were noninferior to injectable somatostatin receptor ligands (iSRLs; octreotide or lanreotide) in maintenance of biochemical control in patients previously responding to both treatments, as well as demonstrated improvements in patient-reported outcomes among patients receiving OOC.Objective:...

0 shares

ea0081oc4.4 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Recurrence in acromegaly: a two tertiary centers experience

Sala Elisa , Cremaschi Arianna , Carosi Giulia , Betella Nazarena , Del Sindaco Giulia , Mangone Alessandra , Mungari Roberta , Pagnano Angela , Indirli Rita , Ferrante Emanuele , Mazziotti Gherardo , Locatelli Marco , Milani Davide , Lania Andrea Gerardo , Arosio Maura , Mantovani Giovanna

The aim of this study was to evaluate in a long follow-up time patients with acromegaly successfully treated by transphenoidal surgery (TNS) in order to establish the recurrence rate and the need of subsequent follow up.Methods: We retrospectively analyzed data of 283 acromegalic patients (168 females, mean age: 44.2 ±12.9 years) who underwent TNS for a GH secreting pituitary adenoma between 1980 and 2020, on regular follow-up at two Pituitary Units...

3 shares

ea0081oc4.5 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Real-world injection experience and use of independent injection among patients using lanreotide autogel/depot (LAN) prefilled syringe or octreotide long-acting release (OCT) to treat acromegaly or neuroendocrine tumors (NETs): international PRESTO 2 survey

Webb Susan , O'Toole Dermot , Kunz Pamela , Houchard Aude , Boiziau Sandra , Ribeiro-Oliveira Antonio , Prebtani Ally

Introduction: Long-acting (LA) somatostatin analog (SSA) therapy is a common first-line medical treatment for acromegaly and NETs. There are limited real-world data on patients injection experience with the latest LA SSA devices/formulations.Aims: To compare the injection experience of patients with acromegaly or NETs who were receiving treatment with LAN prefilled syringe vs OCT syringe.Methods: A 2021 e-survey of adults wit...

0 shares

ea0081oc4.6 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

ACROBAT advance: once daily, oral paltusotine treatment maintained long-term igf-1 at levels previously achieved with injectable long-acting somatostatin receptor ligands (LA-SRLs)

Gadelha Monica R , Randeva Harpal , Gordon Murray B , Mezosi Emese , Doknic Mirjana , Toth Miklos , Boguszewski Cesar L , Nichols Melissa , Jochelson Theresa , Henley Scott , Patel Meenal , Mendez Debbie Koh , Ferrara-Cook Christine , Krasner Alan , Casagrande Alessandra , Struthers R Scott

Paltusotine is a once-daily, oral, nonpeptide somatostatin receptor type 2 (SST2) specific agonist, in development for the treatment of acromegaly and neuroendocrine tumors. We report interim results from ACROBAT Advance (NCT04261712), an ongoing, multicenter, open-label, long-term extension study of paltusotine in subjects with acromegaly who previously completed either Phase 2 study ACROBAT Edge (NCT03789656) or Evolve (NCT03792555). ACROBAT Edge enrolled 47 subjects with el...

0 shares

Endocrine Abstracts

European Congress of Endocrinology 2022